Supplementary Materials Data Availability Statement The atomic coordinates and electron microscopy maps have been deposited in the Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) under accession codes: 9BP3/EMD-44760 [ (Cagri-AMY 1 R-DNG s complex), 9BLW/EMD-44678 [ (CagriBB-AMY 1 R-DNG s complex), 9BQ3/EMD-44796 [ (Cagri-AMY 2 R-DNG s complex), 9BTW]/EMD-44898 [ (Cagri-AMY 3 R-DNG s complex), 9BUB/EMD-44904 [ (Cagri-CTR-DNG s complex 1, bypass conformation), 9BUD/EMD-44906 [ (Cagri-CTR-DNG s complex 1, CT-like conformation), 9BUC/EMD-44905 [ (Cagri-CTR-DNG s complex 2, bypass conformation), 9BUE/EMD-44907 [ (Cagri-CTR-DNG s complex 2, CT-like conformation), 9BLC/EMD-44653 [ (CagriBB-CTR-DNG s complex 1, CT-like conformation), 9BLB/EMD-44652 [ (CagriBB-CTR-DNG s complex 1, bypass conformation)
Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
As of July 2026, no PDUFA (target action) date has been publicly confirmed
Peptides are also used in some FDA-approved medications to treat diabetes, obesity, certain endocrine disorders, and other health conditions
